Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Baxter
McKinsey
Dow
Express Scripts

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 8,536,146

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,536,146
Title:Cytoplasmic BK.sub.Ca channel intron-containing mRNAs contribute to the intrinsic excitability of hippocampal neurons
Abstract: The invention relates to a method of modulating neuronal function by modulating the cytoplasmic level in a neuron of an intron-containing mRNA. The methods are useful in diagnostic, research and therapeutic applications.
Inventor(s): Eberwine; James (Philadelphia, PA), Sul; Jai-Yoon (Bensalem, PA), Bell; Thomas J. (Turnersville, NJ), Miyashiro; Kevin (Philadelphia, PA)
Assignee: The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:12/597,460
Patent Claims:1. A method of decreasing the excitability of a neuron, said method comprising administering to the neuron an siRNA molecule specific for intron-containing KCNMA1 mRNA, wherein the administration of the siRNA molecule specific for intron-containing KNCMA1 mRNA decreases the cytoplasmic level of intron-containing KCNMA1 mRNA in the neuron, wherein the decrease in the cytoplasmic level of intron-containing KCNMA1 mRNA causes a decrease in the excitability of the neuron.

2. The method of claim 1, wherein said intron-containing KCNMA1 mRNA comprises intron 16.

3. The method of claim 2, wherein said intron 16-containing KCNMA1 mRNA further comprises exon 17 spliced directly to exon 18.

4. The method of claim 1, wherein decreasing the cytoplasmic level of intron-containing KCNMA1 mRNA causes a change in distribution of BK.sub.Ca channels in the neuron.

5. A method of modulating the function of a neuron, said method comprising administering to the neuron an siRNA molecule specific for intron-containing KCNMA1 mRNA, wherein the administration of the siRNA molecule specific for intron-containing KNCMA1 mRNA decreases the cytoplasmic level of intron-containing KCNMA1 mRNA in the neuron, wherein the decrease in the cytoplasmic level of intron-containing KCNMA1 mRNA modulates the function of the neuron.

6. The method of claim 5, wherein the intron-containing KCNMA1 mRNA is dendritically targeted.

7. The method of claim 1, wherein the siRNA molecule specific for intron-containing KCNMA1 mRNA comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33 and SEQ ID NO:34.

8. The method of claim 5 wherein the siRNA molecule specific for intron-containing KCNMA1 mRNA comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33 and SEQ ID NO:34.

Details for Patent 8,536,146

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Try it Free 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try it Free 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Colorcon
Medtronic
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.